Cirrus Therapeutics is an ocular immunology-focused company developing treatments for long-term eye diseases that can cause blindness, focusing on conditions that affect the ocular immune system. This company is a spin-out from the University of Bristol.

The company's lead program is a differentiated and first-in-class approach to treating dry age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Cirrus’ novel approach not only addresses the multiple pathways involved in treating AMD but also offers the most compelling and evidence-based strategy available today.